USPTO Patent Application: Beta-1,3'-galactosyllactose for Gut Barrier Function Diseases

ChangeBridge: Patent Apps - Pharma (A61K)

Published November 24th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083764A1) from N.V. Nutricia detailing the use of beta-1,3'-galactosyllactose for treating gut barrier function diseases, particularly in infants and young children. The application was filed on November 24, 2025.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083764A1) filed by N.V. Nutricia on November 24, 2025. The application claims the use of beta-1,3'-galactosyllactose for improving gut barrier function, specifically for subjects at risk of increased gut barrier permeability, such as infants and young children.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in the pharmaceutical and food ingredient sectors related to gut health. Companies involved in infant nutrition, functional foods, or pharmaceutical development for gastrointestinal conditions should be aware of this patent filing.

Source document (simplified)

← USPTO Patent Applications

BETA-1,3'-GALACTOSYLLACTOSE FOR THE TREATMENT OF GUT BARRIER FUNCTION DISEASES

Application US20260083764A1 Kind: A1 Mar 26, 2026

Assignee

N.V. Nutricia

Inventors

Saskia Braber, Belinda Potappel - van 't Land, Selma Paulien Wiertsema, Johan Garssen, Bernd Stahl, Marko Mank

Abstract

The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.